Obesity is complex chronic disease influenced by genetics, hormones, metabolism, environmental factors, and behavior. Over 1 billion people are affected with Obesity in the world. It is a silent epidemic. While diet, exercise, and behavioral modifications remain the cornerstone of weight management, a new generation of anti-obesity medications has transformed the treatment landscape. Most of these medications belong to the glucagon-like peptide-1 (GLP-1) receptor agonist class or combine GLP-1 with glucose-dependent insulinotropic polypeptide (GIP) receptor agonism, resulting in greater weight reduction than previously achievable with pharmacotherapy. Commonly used new weight loss drugs are,
Semaglutide: Semaglutide is a GLP-1 receptor agonist initially developed for type 2 diabetes but later approved in higher doses for obesity management. Administered once weekly by subcutaneous injection, it can produce an average weight loss of approximately 10–15% of baseline body weight when combined with lifestyle modifications.
Tirzepatide: Tirzepatide is a dual GIP and GLP-1 receptor agonist. Clinical trials have demonstrated remarkable weight reductions of 15–22%, making it one of the most effective medications currently available for obesity treatment. It also significantly improves glycemic control in patients with type 2 diabetes.
Liraglutide: Liraglutide is another GLP-1 receptor agonist administered as a daily injection. Although effective, it generally produces less weight loss than semaglutide and tirzepatide.
Benefits of these medications:
- Significant Weight Reduction
- Better Blood Sugar Control
- Cardiovascular Benefits (reduce the risk of major adverse cardiovascular events)
- Improved Blood Pressure and Lipid Profile
- Reduced Appetite
- Improvement in Fatty Liver Disease
- Better Quality of Life
Limitations or Drawbacks:
- High Cost
- Long-Term Treatment Required
- Injectable Formulations
- Not Suitable for Everyone
Under research: Triple hormone agonists targeting GLP-1, GIP, and glucagon receptors are showing even greater weight loss in clinical trials. Scientists are also developing oral peptide formulations, longer-acting injectable medications, and personalized obesity treatments based on genetic and metabolic profiles.
Studies have shown that some of the newest weight loss medications can reduce body weight by more than 20% in selected patients—an amount previously achievable mainly through bariatric surgery. This remarkable progress is changing the way obesity is treated, shifting the focus from willpower alone to evidence-based medical therapy.
Who do you think are ideal candidates for these medication?
MBH/DB